Studies have shown that TP53 mutations can predict the therapeutic effect of PD-1/PD-L1 inhibitors in non-small cell lung cancer (patients with TP53 mutation have a higher overall survival rate after immunotherapy) [44]. Here, TP53 is linked to non-small cell lung carcinoma.